Stellaromics key facts
as of Oct 2026- Developer of gene expression analysis technology designed to study optically extract multi-omic information from biological tissue.
- Stellaromics is valued at approximately $163.0M as of Oct 2026 (last reported valuation).
- It has raised $105.0M; the latest was Early Stage VC ($80.0M) in Dec 2024.
- Notable investors include Stanford University Venture Fund, Bayshore Global Management, Catalyst4, Falcon Creek Capital, Plaisance Capital Management.
- Status: Privately Held (backing).
Stellaromics's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·Watch Stellaromics: the Monday email on marks, rounds and moves
Stellaromics funding rounds
No funding rounds for Stellaromics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Stellaromics valuation
Stellaromics's last reported valuation was $163 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
Stellaromics investors
5 investors are on record for Stellaromics, including Stanford University Venture Fund, Bayshore Global Management, Catalyst4 and Falcon Creek Capital.
About Stellaromics
Developer of gene expression analysis technology designed to study optically extract multi-omic information from biological tissue. The company's tools use patented novel technology for identifying high-resolution three-dimensional transcription patterns in native biological tissue using hydrogel tissue chemistry, allowing researchers to conduct studies on thick tissue samples, and mapping gene expression patterns while preserving the spatial integrity and anatomical structure of the cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 49
- Website
- stellaromics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.